These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30603263)

  • 1. Predictors for achieving target glycemic control in Japanese patients with type 2 diabetes after initiation of basal supported oral therapy using insulin glargine: sub-analysis of the ALOHA2 study, drug use surveillance in Japan.
    Ikeda Y; Tsukube S; Kadowaki T; Odawara M
    Diabetol Int; 2016 Jun; 7(2):188-198. PubMed ID: 30603263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety assessment of basal supported oral therapy (BOT) with insulin glargine in a real-life clinical setting, stratified by concomitant orally administered antidiabetic agent (OAD) regimens including dipeptidyl peptidase-4 inhibitor (DPP-4i): subanalysis of the ALOHA2 study, drug-use surveillance in Japan.
    Tsukube S; Kadowaki T; Odawara M
    Diabetol Int; 2016 Sep; 7(3):299-307. PubMed ID: 30603277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulin-naive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus® to Oral Hypoglycemic Agents (ALOHA) study.
    Odawara M; Kadowaki T; Naito Y
    J Diabetes Complications; 2015; 29(1):127-33. PubMed ID: 25449981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Treatment Satisfaction and Self-reported Health Status after Introduction of Basal-Supported Oral Therapy Using Insulin Glargine in Patients with Type 2 Diabetes: Sub-Analysis of ALOHA2 Study.
    Tsukube S; Ikeda Y; Kadowaki T; Odawara M
    Diabetes Ther; 2015 Jun; 6(2):153-71. PubMed ID: 26040914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing of insulin glargine to achieve the treatment target in Japanese type 2 diabetes on a basal supported oral therapy regimen in real life: ALOHA study subanalysis.
    Odawara M; Ohtani T; Kadowaki T
    Diabetes Technol Ther; 2012 Jul; 14(7):635-43. PubMed ID: 22524524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
    Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
    Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial.
    Miser WF; Arakaki R; Jiang H; Scism-Bacon J; Anderson PW; Fahrbach JL
    Clin Ther; 2010 May; 32(5):896-908. PubMed ID: 20685497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
    Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
    Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which Patients Will Benefit from a Switch in Therapy from Premixed Insulin to Insulin Glargine plus Oral Antidiabetic Drugs? Further Analysis of the Lantus Registry Study.
    Bu S; Zhang X; Zhu H; Shuai Y; Xing X; Yang W;
    Diabetes Ther; 2017 Aug; 8(4):887-898. PubMed ID: 28623551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictor variables and an equation for estimating HbA1c attainable by initiation of basal supported oral therapy.
    Fujita N; Tsujii S; Kuwata H; Kurokawa R; Matsunaga S; Okamura S; Mashitani T; Furuya M; Kitatani M; Ishii H
    J Diabetes Investig; 2012 Mar; 3(2):164-9. PubMed ID: 24843560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential formula for the calculation of starting and incremental insulin glargine doses: ALOHA subanalysis.
    Kadowaki T; Ohtani T; Naito Y; Odawara M
    PLoS One; 2012; 7(8):e41358. PubMed ID: 22870214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study.
    Hong EG; Min KW; Lim JS; Ahn KJ; Ahn CW; Yu JM; Kim HS; Kim HJ; Kim W; Kim DH; Jang HC
    Adv Ther; 2024 May; 41(5):1967-1982. PubMed ID: 38512540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study.
    Matsuhisa M; Miyoshi H; Yabe D; Takahashi Y; Morimoto Y; Terauchi Y
    Diabetes Ther; 2023 Jan; 14(1):219-236. PubMed ID: 36422802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and predictors of hypoglycemia in Japanese patients with type 2 diabetes treated by insulin glargine and oral antidiabetic drugs in real-life: ALOHA post-marketing surveillance study sub-analysis.
    Odawara M; Kadowaki T; Naito Y
    Diabetol Metab Syndr; 2014 Feb; 6(1):20. PubMed ID: 24528773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world setting.
    Pfohl M; Jornayvaz FR; Fritsche A; Pscherer S; Anderten H; Pegelow K; Seufert J
    Diabetes Obes Metab; 2020 May; 22(5):759-766. PubMed ID: 31903680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs.
    Fritsche A; Anderten H; Pfohl M; Pscherer S; Borck A; Pegelow K; Bramlage P; Seufert J
    BMJ Open Diabetes Res Care; 2019; 7(1):e000668. PubMed ID: 31423316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment - A prospective observational study in 2202 patients.
    Siegmund T; Pfohl M; Forst T; Pscherer S; Bramlage P; Foersch J; Borck A; Seufert J
    Diabetes Metab Syndr; 2017; 11(1):51-57. PubMed ID: 27578616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK.
    Davies M; Evans R; Storms F; Gomis R; Khunti K
    Diabetes Obes Metab; 2007 Sep; 9(5):706-13. PubMed ID: 17697063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.